Home Reported Outcomes in C3G Study

Abroad (travel likely)Recruiting

Conditions

C3 Glomerulopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Novartis Investigative Site, East Hanover, New Jersey, United States

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

Paroxysmal Nocturnal Hemoglobinuria · C3 Glomerulopathy

Abroad (travel likely)Recruiting

Jeollanam, South Korea · Seoul, South Korea

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

C3 Glomerulopathy (C3G) · Healthy Adult Participants

Abroad (travel likely)RecruitingPHASE1

Vienna, Austria · Brussels, Belgium

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy · Idiopathic Immune Complex-Mediated Glomerulonephritis

Abroad (travel likely)RecruitingPHASE2

Kaunas, Lithuania · Vilnius, Lithuania

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 Glomerulopathy · Membranoproliferative Glomerulonephritis · Complement Abnormality

Abroad (travel likely)RecruitingPHASE2

Gothenburg, Sweden · Lund, Sweden